



JC-REGISTRATION 15 FEB 2002

PATENT  
3631-112P

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: KLYSNER, Steen Conf.: 2292  
Appl. No.: 09/980,916 Group: unassigned  
Filed: October 23, 2001 Examiner: UNASSIGNED  
For: METHOD FOR DOWN-REGULATING IL5 ACTIVITY

INFORMATION DISCLOSURE STATEMENT  
(SUBMISSION AFTER FILING OF AN APPLICATION  
BUT BEFORE FINAL REJECTION OR NOTICE OF ALLOWANCE  
OR CONCURRENTLY WITH A RULE 53(d) CPA APPLICATION  
OR WITH A RULE 1.114 RCE APPLICATION)

Assistant Commissioner for Patents  
Washington, DC 20231

January 24, 2002

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications, or other information submitted for consideration by the Office are listed on the PTO-1449(s), attached hereto.

II. COPIES (check at least one box)

- a. ☒ Submitted herewith is a legible copy of (i) each U.S. and foreign patent; (ii) each publication or that portion which caused it to be listed; and (iii) all other information or that portion which caused it to be listed.
- b. ☐ Some or all of the documents listed on the PTO-1449 are not enclosed because they were cited in the International Search Report and copies should already be in the PTO file. If copies are needed, please contact the undersigned.

III. CONCISE EXPLANATION OF THE RELEVANCE  
(check at least one box)

a. ☒ **DOCUMENTS IN THE ENGLISH LANGUAGE**

The attached patents, publications, or other information in the English language do not require a statement of relevancy.

b. ☐ **DOCUMENTS NOT IN THE ENGLISH LANGUAGE**

A concise explanation of the relevance of all patents, publications, or other information listed that is not in the English language is as follows:

c. ☐ **ENGLISH LANGUAGE SEARCH REPORT**

An English language version of the search report or action that indicates the degree of relevance found by the foreign office is attached, thereby satisfying the requirement for a concise explanation. See MPEP 609(A)(3).

d. ☐ **OTHER**

The following additional information is provided for the Examiner's consideration.

FEES

IV. ☒ THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(b):  
(check one box)

- a. ☐ within three months of the filing date of a national application (37 C.F.R. § 1.97(b)(1)). No fee or statement is required. (This section is not to be used with RCE's and CPA's).
- b. ☐ within three months of the date of entry of the national stage as set forth in § 1.491 in an international application (37 C.F.R. § 1.97(b)(2)). No fee or statement is required.
- c. ☐ concurrently with the filing of a Continued Prosecution Application under 37 C.F.R. § 1.53(d) or concurrently with the filing of a Request for Continued Examination under § 1.114 (37 C.F.R. § 1.97(b)(4)). No fee or statement is required.
- d. ☒ before the mailing date of a first Action on the merits (37 C.F.R. § 1.97(b)(3)). No fee or statement is required.  
In the event that a first Office Action on the merits has been issued, please consider this IDS under 37 C.F.R. § 1.97(c) and see the statement under 37 C.F.R. § 1.97(e) below, or, if no statement has been made, charge our deposit account in the amount of \$180.00 as required by 37 C.F.R. § 1.17(p).

V. ☐ THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(c):  
(check one box)

before the mailing date of a Final Office Action under 37 C.F.R. § 1.113 (See 37 C.F.R. § 1.97(c)(1)), or before the mailing date of a Notice of Allowance under 37 C.F.R. § 1.311 (See 37 C.F.R. § 1.97(c)(2)).

- a. ☐ No statement; therefore, a fee in the amount of \$180.00 as required by 37 C.F.R. § 1.17(p).  
or
- b. ☐ See the statement below. No fee is required.

VI. STATEMENT UNDER 37 C.F.R. § 1.97(e) (check only one box)

The undersigned hereby states that

- a. ☐ each item of information contained in the IDS was first cited in any communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS; or
- b. ☐ no item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of IDS was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of the IDS.
- c. ☐ Some of the items of information were cited in a communication from a foreign Patent Office. As to this information, the undersigned states that each item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby states that no item of this remaining information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application and, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.

VII. PAYMENT OF FEES (check one box)

- ☐ A check in the amount of \$130.00 as required by 37 C.F.R. § 1.17(p) is enclosed for the above-identified fee.
- ☐ Please charge Deposit Account No. 02-2448 in the amount required by 37 C.F.R. § 1.17(p) for the above-indicated fee. A triplicate copy of this paper is attached.
- ☒ No fee is required.

Appl. No. 09/980,916

If the Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule and charge the appropriate fee to Deposit Account No. 02-2448.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP


By   
Leonard R. Svensson, #30,330

LRS/clh  
3631-112P

P.O. Box 747  
Falls Church, VA 22040-0747  
(703) 205-8000

Enclosures: ☒ PTO-1449  
☒ Documents  
☐ Foreign Search Report  
☐ Fee  
☐ Other:

Rev. 11/91/01

3402  
BIRCH, STEWART, KOLASCH & BIRCH, LLP  


[illegible][illegible]

		Nature Biotechnology 17(July 1999) 666-9 Darum et al "Therapeutic antibodies ."
		Intern Rev Immunol 16(1998) 227-47 Karlen et al "Biological and molecular ..."
		J Allergy Clin Immun 103(1999) 222-30 Karsten et al "IL-4-and IL-6-production ."
		The Journal of Immunology 160(1998) 4427-34 Wang et al "TGF-beta inhibition ."
		The Journal of Immunology 160((1998) 3363-73 Southwood et al "Several common ."
		Scand J Immunol 47(1998) 596-602 Ohashi et al "Allergen-induced synthesis ..."

EXAMINER	DATE CONSIDERED
----------	-----------------

[illegible]

INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

$\frac{d}{dt} \left( \frac{\partial L}{\partial \dot{x}} \right) = \frac{\partial L}{\partial x}$

2011年11月11日  
 星期五

## DOCUMENT NUMBER

DOCUMENT NUMBER

(Including Author, Title, Date, Pertinent Pages, etc.)

Allergy, Ed: Kaplan, AB (1993) Orsaga et al Chapter 26, "Asthma"

EXAMINER

09/980,916

FILING DATE  
October 23, 2001

NAME	unassigned
------	------------

INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

[illegible]

U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, etc.)

	Nature Biotechnology 17(July 1999) 686-9 Salum et al "Therapeutic antibodies ."
	Intern Rev Immunol 16(1998) 227-47 Karlen et al "Biological and molecular ..."
	J Allergy Clin Immunol 101(1998) 242-50 Barak et al "IL-4- and IL-5-positive ."
	The Journal of Immunology 160(1998) 4427-32 Wang et al "Selective inhibition ."
	The Journal of Immunology 160((1998) 3363-73 Southwood et al "Several common ."
	Scand J Immunol 47(1998) 596-602 Ohashi et al "Allergen-induced synthesis ..."

EXAMINER

DATE CONSIDERED \_\_\_\_\_

EXAMPLE: In the case of a child born in 1980, with a date of birth of 1980-01-01, the date of birth of the child would be 1980-01-01.



EXAMINER	DATE CONSIDERED
EXAMINER: I have read the above document, and find it contains information which may be of value to the U.S. Patent Office in the examination of the application.	

INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

[illegible][illegible]

		The Journal of Immunology 157(1996) 4796-4804 Darum et al "Breaking of B ..."
		J Mol Med 74(1996) 535-546 Dickason et al "Engineering of a functional ..."
		Journal of Protein Chemistry 15(1996) 491-501 Brink et al "The ..."
		Nature 373(15 February 1996) 447-45 Dickason et al "Creation of a ..."
		Am J Respir Cell Mol Biol 13(1995) 360-65 Kung et al "Involvement of IL-5 ..."
		Am J Respir Crit Care Med 151(1995) 177-83 van Oosterhout et al "Antibody ..."

EXAMINER	DATE CONSIDERED
EXAMINER: Initials of Officer in Charge, whether a member of the staff or with Military, or Civilian, or other, and in what capacity.	

3631-112P

09/980,916

APPLICANT  
KLYSNER, Steen

October 23, 2001

unassigned
------------

U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, etc.)

	Am J Respir Crit Care Med 150(1995) 467-72 Munnich et al "Effector T cell ..."
	Immunology Letters 46(1995) 109-116 Agulston et al "Antibody ..."
	Int Arch Allergy Immunol 107(1994) 111-22 Eisen et al "Inhibition ..."
	The Journal of Biological Chemistry 270(26) (June 30, 1995) 15749-15760 Graber
	The Journal of Immunology 155(1995) 3946-54 Villinger et al "Comparative ..."
	Am J Respir Crit Care Med 150(1994) S50-S53 Cousins et al "Regulation ..."

EXAMINER.

DATE CONSIDERED

CONFIDENTIAL - This document contains information that is exempt from public release under the Freedom of Information Act, 5 U.S.C. 552, and is to be controlled, stored, handled, transmitted, and disposed of in accordance with the provisions of the Department of Defense Information Security Manual, DoD 5200.101, and the Department of Defense Information Security Manual, DoD 5200.101, and the Department of Defense Information Security Manual, DoD 5200.101.

09/980,916

INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

KLYSNER, Steen

October 23, 2001

unassigned
------------

U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, etc.)

	Pharmacol 113(1994) 542-56 Czeifler et al "Effect of Interleukin-1 ..."
	Cytokine 6(6)(November 1994) 641-56 Dickason et al "Enhanced detection ..."
	Immunogenetics 44(1994) 230-242 Falk et al "Effect of suspending ... natural ..."
	Thromb 49(1994) 1031-33 Alexander et al "Serum interleukin-1 ..."
	Am Rev Respir Dis 147(1993) 548-552 van Oosterhout et al "Effect of Anti-IL..."
	Am Rev Respir Dis 148(1993) 1623-27 Mauser et al "Inhibitory effect of the ..."

EXAMINER

DATE	CONSIDERED
------	------------

EXAMINER: [redacted]	DATE: [redacted]	TIME: [redacted]	LOCATION: [redacted]	REMARKS: [redacted]
----------------------	------------------	------------------	----------------------	---------------------

Form 870-1110

NOIPE INFORMATION

FEB 15 2002

PATENT & TRADEMARK OFFICE

...the ... ..

unassigned
------------

[illegible][illegible]

	Annals NY Acad Sci 1993; 685- Nagai et al "The role of interleukin-1 ..."
	Cell 74(July 16, 1993) 137-205 Hammer et al "Promiscuous and allelic ..."
	Eur J Biochem 212(1993) 751-55 Graber et al "Purification, ..."
	Eur J Biochem 211(1993) 223-28 Kiyama et al "Role of sugar chains in ..."
	J Exp Med 178(July 1993) 27-47 Chicz et al "Specificity and promiscuity ..."
	Life Sciences 53(1993) PL 243-47 Nagai et al "Effect of anti-IL-5 ..."

DATE CONSIDERED

[illegible]

09/980,916

ALLIANCE  
KLYSNER, Steen

unassigned
------------

U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, etc.)

	Nature 361 15 May 1991 751-756 Milburn et al "A novel dimer configuration ..."
	Biochem J 266(1992) 625-630 Rose et al "Human interleukin-5 expressed in ..."
	European Journal of Pharmacology 211(1992) 121-123 Chand et al "Anti-IL-5 ..."
	WJ-84 72(1) June 15, 1991 3101-33 Sanders "Interleukin-5, eosinophils ..."
	Immunology Today 13(12(1992) 495-500 Lopez et al "GM-CSF, IL-3 and IL-5 ..."
	Blood 78(10)(November 15, 1991) 2542-47 Yamaguchi et al "Analysis of the ..."

EXAMINER

DATE CONSIDERED

100-443887-1000

09/980,916

FILING DATE  
October 23, 2001

unassigned
------------

*Journal of Management Education* 30(6)p.789-804

U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, etc.)

		"Exp Med 173(February 1991) 429-37 Tominaga et al "Transgenic mice ..."
		Textbook of Medicine, 1990 Ed:Jubani and Moxham, Chap 14 "Respiratory Disease"
		Biochem J 270(1991) 457-61 in Wilson et al "Preparation and ..."
		The Journal of Immunology 145(11)(December 1990) 3911-16 Sher et al "Ablation "
		The Journal of Immunology 144(4)(February 15, 1990) 1345-52 Tominaga et al "
		DNA 8(7)(1989) Tavernier et al "Expression of human and murine ..."

EXAMINER

DATE CONSIDERED
-----------------

[illegible]

3631-112P

09/980,916

INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

APPLICANT  
KLYSNER, Steen

FILING DATE  
October 23, 2001

unassigned
------------

FEB 15 2002

The total stops is approximately

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, etc.)

	Science 245(July 21, 1989) 308-10 Goffman et al "Antibody to interleukin-5..."
	Eur J Biochem 174(1988) 345-48 Campbell et al "Isolation, structure..."
	Nature 336(December 22/29 1988) 778-80 Sinigaglia et al "A malaria t-cell..."
	The Journal of Biological Chemistry 262(34)(December 5, 1987) 16580-4 Tanabe
	Nucleic Acids Research 14(22)(1986) Azuma et al "Cloning of cDNA for..."

EXAMINER

DATE CONSIDERED

[illegible]



FEB 15 2002

09/980,916

APPELLANT  
KLYSNER, Steen

FILING DATE  
October 23, 2001

GROUP
Unassigned

[illegible][illegible]

		Cytokine and Growth Factor Reviews, 9(1) 25-35 (1998) Takatsu "Interleukin ..."
		Allergy and Asthma Proc.(Sept/Oct 1998) 19(5) 257-61 Weltman et al
		J. of Allergy and Clinical Immunology, 99(1), Part 2 Broide et al

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

